IMMUNOCORE HOLDINGS PLC-ADR (IMCR) Stock Fundamental Analysis

NASDAQ:IMCR • US45258D1054

32.38 USD
+0.1 (+0.31%)
At close: Feb 17, 2026
32.38 USD
0 (0%)
After Hours: 2/17/2026, 8:23:47 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to IMCR. IMCR was compared to 521 industry peers in the Biotechnology industry. The financial health of IMCR is average, but there are quite some concerns on its profitability. While showing a medium growth rate, IMCR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year IMCR has reported negative net income.
  • IMCR had a positive operating cash flow in the past year.
  • In the past 5 years IMCR always reported negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: IMCR reported negative operating cash flow in multiple years.
IMCR Yearly Net Income VS EBIT VS OCF VS FCFIMCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

  • IMCR's Return On Assets of -2.65% is amongst the best of the industry. IMCR outperforms 87.33% of its industry peers.
  • IMCR's Return On Equity of -7.37% is amongst the best of the industry. IMCR outperforms 88.87% of its industry peers.
Industry RankSector Rank
ROA -2.65%
ROE -7.37%
ROIC N/A
ROA(3y)-7.93%
ROA(5y)-20.99%
ROE(3y)-14.64%
ROE(5y)-50.92%
ROIC(3y)N/A
ROIC(5y)N/A
IMCR Yearly ROA, ROE, ROICIMCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

  • Looking at the Gross Margin, with a value of 99.28%, IMCR belongs to the top of the industry, outperforming 98.46% of the companies in the same industry.
  • IMCR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.29%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMCR Yearly Profit, Operating, Gross MarginsIMCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • IMCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for IMCR remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, IMCR has more shares outstanding
  • IMCR has a worse debt/assets ratio than last year.
IMCR Yearly Shares OutstandingIMCR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
IMCR Yearly Total Debt VS Total AssetsIMCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • IMCR has an Altman-Z score of 1.51. This is a bad value and indicates that IMCR is not financially healthy and even has some risk of bankruptcy.
  • IMCR has a better Altman-Z score (1.51) than 64.68% of its industry peers.
  • The Debt to FCF ratio of IMCR is 133.17, which is on the high side as it means it would take IMCR, 133.17 years of fcf income to pay off all of its debts.
  • IMCR has a Debt to FCF ratio of 133.17. This is amongst the best in the industry. IMCR outperforms 89.44% of its industry peers.
  • A Debt/Equity ratio of 0.99 indicates that IMCR is somewhat dependend on debt financing.
  • IMCR has a worse Debt to Equity ratio (0.99) than 74.66% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.99
Debt/FCF 133.17
Altman-Z 1.51
ROIC/WACCN/A
WACC8.69%
IMCR Yearly LT Debt VS Equity VS FCFIMCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 6.00 indicates that IMCR has no problem at all paying its short term obligations.
  • IMCR has a Current ratio of 6.00. This is in the better half of the industry: IMCR outperforms 62.38% of its industry peers.
  • A Quick Ratio of 5.97 indicates that IMCR has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 5.97, IMCR is doing good in the industry, outperforming 63.34% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6
Quick Ratio 5.97
IMCR Yearly Current Assets VS Current LiabilitesIMCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 40.00% over the past year.
  • The Revenue for IMCR has decreased by -20.18% in the past year. This is quite bad
  • Measured over the past years, IMCR shows a very strong growth in Revenue. The Revenue has been growing by 64.57% on average per year.
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)-20.18%
Revenue growth 3Y127.06%
Revenue growth 5Y64.57%
Sales Q2Q%29.22%

3.2 Future

  • The Earnings Per Share is expected to grow by 36.63% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, IMCR will show a very strong growth in Revenue. The Revenue will grow by 21.89% on average per year.
EPS Next Y66.47%
EPS Next 2Y-1.62%
EPS Next 3Y-2.82%
EPS Next 5Y36.63%
Revenue Next Year27.84%
Revenue Next 2Y19.15%
Revenue Next 3Y16.78%
Revenue Next 5Y21.89%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
IMCR Yearly Revenue VS EstimatesIMCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
IMCR Yearly EPS VS EstimatesIMCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IMCR. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMCR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMCR Price Earnings VS Forward Price EarningsIMCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of IMCR indicates a rather cheap valuation: IMCR is cheaper than 89.25% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 555.01
EV/EBITDA N/A
IMCR Per share dataIMCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • A cheap valuation may be justified as IMCR's earnings are expected to decrease with -2.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.62%
EPS Next 3Y-2.82%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for IMCR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IMMUNOCORE HOLDINGS PLC-ADR

NASDAQ:IMCR (2/17/2026, 8:23:47 PM)

After market: 32.38 0 (0%)

32.38

+0.1 (+0.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)02-24
Inst Owners100.26%
Inst Owner Change3.06%
Ins Owners0.03%
Ins Owner Change0%
Market Cap1.64B
Revenue(TTM)379.59M
Net Income(TTM)-29.23M
Analysts83.48
Price Target69.17 (113.62%)
Short Float %22.13%
Short Ratio27.41
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)50.15%
Min EPS beat(2)0.3%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)36.51%
Min EPS beat(4)-79.43%
Max EPS beat(4)125.17%
EPS beat(8)5
Avg EPS beat(8)33.88%
EPS beat(12)7
Avg EPS beat(12)-172519%
EPS beat(16)10
Avg EPS beat(16)-129372%
Revenue beat(2)2
Avg Revenue beat(2)1.41%
Min Revenue beat(2)1.34%
Max Revenue beat(2)1.47%
Revenue beat(4)3
Avg Revenue beat(4)0.81%
Min Revenue beat(4)-4.08%
Max Revenue beat(4)4.49%
Revenue beat(8)4
Avg Revenue beat(8)-0.21%
Revenue beat(12)5
Avg Revenue beat(12)-2.15%
Revenue beat(16)8
Avg Revenue beat(16)13.17%
PT rev (1m)-0.86%
PT rev (3m)2.94%
EPS NQ rev (1m)-3.18%
EPS NQ rev (3m)13.22%
EPS NY rev (1m)10.41%
EPS NY rev (3m)53.39%
Revenue NQ rev (1m)-0.2%
Revenue NQ rev (3m)2.41%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)1.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.31
P/FCF 555.01
P/OCF 204.73
P/B 4.13
P/tB 4.13
EV/EBITDA N/A
EPS(TTM)-0.57
EYN/A
EPS(NY)-1.05
Fwd EYN/A
FCF(TTM)0.06
FCFY0.18%
OCF(TTM)0.16
OCFY0.49%
SpS7.51
BVpS7.85
TBVpS7.85
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.65%
ROE -7.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.29%
FCFM 0.78%
ROA(3y)-7.93%
ROA(5y)-20.99%
ROE(3y)-14.64%
ROE(5y)-50.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.99
Debt/FCF 133.17
Debt/EBITDA N/A
Cap/Depr 140.19%
Cap/Sales 1.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6
Quick Ratio 5.97
Altman-Z 1.51
F-Score6
WACC8.69%
ROIC/WACCN/A
Cap/Depr(3y)97.19%
Cap/Depr(5y)68.03%
Cap/Sales(3y)1.79%
Cap/Sales(5y)3.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y66.47%
EPS Next 2Y-1.62%
EPS Next 3Y-2.82%
EPS Next 5Y36.63%
Revenue 1Y (TTM)-20.18%
Revenue growth 3Y127.06%
Revenue growth 5Y64.57%
Sales Q2Q%29.22%
Revenue Next Year27.84%
Revenue Next 2Y19.15%
Revenue Next 3Y16.78%
Revenue Next 5Y21.89%
EBIT growth 1Y59.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year42.29%
EBIT Next 3Y-3.26%
EBIT Next 5Y36.15%
FCF growth 1Y-77.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.3%
OCF growth 3YN/A
OCF growth 5YN/A

IMMUNOCORE HOLDINGS PLC-ADR / IMCR FAQ

What is the ChartMill fundamental rating of IMMUNOCORE HOLDINGS PLC-ADR (IMCR) stock?

ChartMill assigns a fundamental rating of 4 / 10 to IMCR.


What is the valuation status for IMCR stock?

ChartMill assigns a valuation rating of 2 / 10 to IMMUNOCORE HOLDINGS PLC-ADR (IMCR). This can be considered as Overvalued.


How profitable is IMMUNOCORE HOLDINGS PLC-ADR (IMCR) stock?

IMMUNOCORE HOLDINGS PLC-ADR (IMCR) has a profitability rating of 3 / 10.


Can you provide the financial health for IMCR stock?

The financial health rating of IMMUNOCORE HOLDINGS PLC-ADR (IMCR) is 5 / 10.